Lab 21 offers KRAS / NRAS / BRAF testing via NGS for a fully comprehensive result. Recent data suggest that, together with KRAS mutations, the evaluation of mutational status of other genes can be helpful in predicting prognosis/response to treatment.
Lab 21 Ltd can offer targeted testing of KRAS, NRAS and BRAF by Next Generation Sequencing which screens for specific reported mutations within codons 12, 13, 59, 61 and 146 of the KRAS gene, codons 12, 13, 59 and 61 of the NRAS gene and codon 600 of the BRAF gene.
These assays can detect mutations at KRAS cDNA positions c.34, c.35, c.37, c.38, c.175, c.176, c.177 c.181, c.182, c.183 c.436 and c.437, which account for >95% of all KRAS mutations, mutations at NRAS cDNA positions c.34, c.35, c.37, c.38, c.175, c.176, c.177, c.181, c.182, c.183, which account for >95% of all NRAS mutations in colorectal cancer and mutations at BRAF cDNA positions c.1797, c.1798, c.1799, c.1800 and c.1801 which account for >95% of all BRAF mutations in colorectal cancer.
The standard turnaround time (TAT) is generally 7-10 days.
Information for test processing
To request KRAS/NRAS/BRAF testing, the first point of contact is the dedicated Lab 21 Customer Services Team who handle:
- Test Requests and Customer Support
- Liaison with Sample Retention Sites for sample retrieval if required
- Reporting of the results
Not provided under our UKAS accreditation.
Please see our Accreditation page for full scope of accredited testing.
10 slides (at 5-10 microns) plus H&E with tumour % estimate.